GlassScriptPhysician profile
Archana Maini
NPI 1942211370
$20,407.14
in general payments reported to CMS, 2019-2025
44 companies · $117 in 2025
The $117 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,595 · 2020: $7,111 · 2021: $1,983 · 2022: $1,768 · 2023: $1,604 · 2024: $229 · 2025: $117.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,643 · Education: $308.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,643.19 |
| Education | $307.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $7,834.17 | 2019-2023 | |
| Ipsen Biopharmaceuticals, INC | $2,117.17 | 2020-2021 | |
| Glaxosmithkline, LLC. | $1,950.00 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $1,917.24 | 2020-2023 | |
| Astrazeneca Pharmaceuticals LP | $763.94 | 2020-2025 | Imfinzi, Tagrisso |
| Pfizer INC. | $719.57 | 2020-2025 | |
| Janssen Biotech, INC. | $641.90 | 2020-2024 | Darzalex, Erleada, Tecvayli |
| Rigel Pharmaceuticals, INC. | $482.69 | 2020-2023 | Rezlidhia, Tavalisse |
| Celgene Corporation | $365.79 | 2020-2023 | Pomalyst, Reblozyl |
| Merck Sharp & Dohme LLC | $348.16 | 2020-2023 | Keytruda, Welireg, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $328.53 | 2020-2023 | Opdivo |
| Astellas Pharma US INC | $288.74 | 2020-2023 | Xtandi, Xospata, Padcev |
| Incyte Corporation | $262.67 | 2019-2022 | |
| Eisai INC. | $238.15 | 2020-2023 | |
| Seagen INC. | $223.15 | 2020-2022 |
Show all 43 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Archana Maini listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.